Pyelonephritis

SPRO FINAL DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Spero Therapeutics, Inc. Investors With Losses Over $100K to Secure Counsel Before Important July 25 Deadline in Securities Class Action – SPRO

Retrieved on: 
Thursday, July 21, 2022
Titan, Urinary tract infection, GLOBE, Tebipenem, Court, Food and Drug Administration, Twitter, Food, Class, New Drug Application, Workforce, NDA, WHY, Advertising, NASDAQ, THE, Facebook, I-Space (Chinese company), FDA, LinkedIn, Pyelonephritis, Lists of schools in England, Spero, TO, Medical device, Insurance, Tobacco

WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.
  • If you wish to serve as lead plaintiff, you must move the Court no later than July 25, 2022.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022

Retrieved on: 
Wednesday, July 20, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MRSA, Patient, Streptococcus agalactiae, MSSA, Streptococcus anginosus group, Bacteria, Food and Drug Administration, Tablet, Culture, Drug of last resort, Marketing, Pyelonephritis, ABSSSI, Review, Staphylococcus aureus, Infection, Streptococcus constellatus, Diarrhea, U.S. Securities and Exchange Commission, Human, Union, Research, Enterococcus, Merck, Moxifloxacin, Streptococcus intermedius, Private Securities Litigation Reform Act, Urinary tract infection, GLOBE, Streptococcus anginosus, Food, COVID-19, Conference, Nausea, Streptococcus pyogenes, Vomiting, Cutis laxa, Linezolid, Fosfomycin, Enterococcus faecalis, Bronchopneumonia, Complicated, Therapy, NASDAQ, Gram, Cystic fibrosis, Pharmaceutical industry, Streptococcus

ET to discuss the financial results and recent corporate highlights.

Key Points: 
  • ET to discuss the financial results and recent corporate highlights.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
  • However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Pomerantz Law Firm Announces the Filing of a Class Action Against Spero Therapeutics, Inc. and Certain Officers – SPRO

Retrieved on: 
Monday, July 18, 2022
News, District court, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MDR, Person, SEC Rule 10b-5, LLP, Review, Lists of action films, GLOBE, Securities Exchange Act of 1934, Food, Urinary tract infection, Lists of schools in England, Tebipenem, Complicated, LCM, New Drug Application, HBR, Complaint, Ext, NASDAQ, Infection, Company, NDA, Court, Degenerative disease, Pomerantz, FDA, Treatment, Workforce, Population, Pharmaceutical industry, Renewable energy, Spero, Pyelonephritis

NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO) and certain of its officers.

Key Points: 
  • NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members.

Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticals

Retrieved on: 
Monday, July 18, 2022
Nausea, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Intermediary, Bacteria, Bacterial pneumonia, Cutis marmorata telangiectatica congenita, Diarrhea, GLOBE, Food, Urinary tract infection, Fosfomycin, Infection, Moxifloxacin, Marketing, Human, Linezolid, Pyelonephritis, NASDAQ, Tablet, Vomiting, COVID-19, Bronchopneumonia, Food and Drug Administration, Therapy, Merck, NPU, Pharmaceutical industry

Nabriva will be the exclusive supplier of XENLETA to Er-Kim.

Key Points: 
  • Nabriva will be the exclusive supplier of XENLETA to Er-Kim.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
  • XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics team.

ROSEN, A TOP RANKED LAW FIRM, Encourages Spero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRO

Retrieved on: 
Sunday, July 17, 2022
Titan, Advertising, WHY, Facebook, THE, LinkedIn, Spero, I-Space (Chinese company), GLOBE, Food, Urinary tract infection, Twitter, Lists of schools in England, Pyelonephritis, Tebipenem, New Drug Application, NASDAQ, Class, NDA, Food and Drug Administration, TO, Court, FDA, Workforce, Medical device, Insurance, Tobacco

WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CareDx, Spero, LMP, and Dentsply Sirona and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, July 16, 2022
News, Audit committee, LMP, Spero, Review, Board, Kidney, Company, Government, California superior courts, Population, Medicare, SEC, Dentsply Sirona, Relevant, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Annual report, Food, Income, Complaint, NASDAQ, Physician, Anesthetic, Defendant, Patient, Class Action, Urinary tract infection, Lists of schools in England, Tebipenem, CDNA, Superior, Degenerative disease, COVID-19, XRAY, NDA, Risk, Growth, Plaque, Workforce, Justice, Mission statement, GLOBE, Complicated, New Drug Application, Marketing, Documentation, Infection, Sale, FDA, ASP, Treatment, HBR, Pharmaceutical industry, Animal, Renewable energy, Audit, Medical device, Property management, P.C, Pyelonephritis

Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.

Key Points: 
  • Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.
  • In order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the Class Period.
  • For more information on the Dentsply Sirona class action go to: https://bespc.com/cases/XRAY
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CareDx, Spero, LMP, and Dentsply Sirona and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, July 11, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HBR, Defendant, Treatment, Superior, Mission statement, Review, New Drug Application, GLOBE, Degenerative disease, Medicare, Lists of schools in England, Spero, Plaque, News, Population, NDA, Class Action, LMP, Tebipenem, Marketing, Government, Income, Relevant, Patient, SEC, Growth, Complicated, Physician, California superior courts, XRAY, Infection, Annual report, Urinary tract infection, Audit committee, CDNA, Justice, Food, Company, ASP, Dentsply Sirona, Anesthetic, Workforce, Kidney, COVID-19, Risk, Sale, Board, Documentation, NASDAQ, Complaint, Pharmaceutical industry, Animal, Renewable energy, Audit, Medical device, Property management, Pyelonephritis, P.C

Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.

Key Points: 
  • Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.
  • In order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the Class Period.
  • For more information on the Dentsply Sirona class action go to: https://bespc.com/cases/XRAY
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – SPRO

Retrieved on: 
Sunday, July 10, 2022
Titan, FDA, I-Space (Chinese company), Urinary tract infection, Advertising, LinkedIn, Court, New Drug Application, TO, WHY, Workforce, Food and Drug Administration, GLOBE, Class, Pyelonephritis, Tebipenem, Lists of schools in England, Food, THE, Spero, Facebook, NASDAQ, Twitter, NDA, Medical device, Insurance, Tobacco

WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spero Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – SPRO

Retrieved on: 
Saturday, July 9, 2022
Review, FDA, Urinary tract infection, Patient, Securities Exchange Act of 1934, Treatment, Court, Infection, LLP, Workforce, GLOBE, Population, Degenerative disease, Company, District court, Complicated, Tebipenem, Lists of schools in England, Pomerantz, Ext, Food, Person, HBR, Lists of action films, Complaint, New Drug Application, NASDAQ, SEC Rule 10b-5, News, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, Pharmaceutical industry, Renewable energy, Spero, Pyelonephritis

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • On March 31, 2022, Spero issued a press release announcing the Companys fourth quarter and full year 2021 financial results.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CareDx, Spero, LMP, and Dentsply Sirona and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, July 5, 2022
XRAY, Urinary tract infection, Patient, Treatment, GLOBE, Marketing, COVID-19, Growth, Degenerative disease, Company, Complicated, Annual report, CDNA, Food, Mission statement, HBR, Class Action, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, FDA, Population, Tebipenem, Plaque, Dentsply Sirona, SEC, Income, Documentation, Defendant, Workforce, Kidney, New Drug Application, NASDAQ, Board, Medicare, News, ASP, Complaint, Review, California superior courts, Justice, Audit committee, Infection, Sale, Lists of schools in England, Relevant, Risk, LMP, Superior, Spero, Anesthetic, Government, Physician, Pharmaceutical industry, Animal, Renewable energy, Audit, Medical device, Property management, P.C, Pyelonephritis

Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.

Key Points: 
  • Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.
  • In order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the Class Period.
  • For more information on the Dentsply Sirona class action go to: https://bespc.com/cases/XRAY
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.